The PE Ratio as of November 2024 (TTM) for Mustang Bio, Inc. (MBIO) is -0.15

According to Mustang Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.15. This represents a change of -76.72% compared to the average of -0.64 of the last 4 quarters.

Mustang Bio, Inc. (MBIO) Historical PE Ratio (quarterly & annually)

How has MBIO PE Ratio performed in the past?

The mean historical PE Ratio of Mustang Bio, Inc. over the last ten years is -7.09. The current -0.15 PE Ratio has changed 111.65% with respect to the historical average. Over the past ten years (40 quarters), MBIO's PE Ratio was at its highest in in the June 2024 quarter at -0.11. The PE Ratio was at its lowest in in the March 2016 quarter at -71.17.

Mustang Bio, Inc. (MBIO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Mustang Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mustang Bio, Inc. (MBIO) Average PE Ratio

How has MBIO PE Ratio performed in the past?

The current PE Ratio of Mustang Bio, Inc. (MBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Mustang Bio, Inc. (MBIO) PE Ratio vs. Peers

How is MBIO’s PE Ratio compared to its peers?

Mustang Bio, Inc.’s PE Ratio is greater than Checkpoint Therapeutics, Inc. (-3.48), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.19), greater than Fortress Biotech, Inc. (-0.62), greater than Kodiak Sciences Inc. (-1.70), greater than Fortress Biotech, Inc. (-0.62), greater than Achilles Therapeutics plc (-0.64), less than Aptose Biosciences Inc. (-0.10), less than Aditxt, Inc. (-0.00), greater than NeuroBo Pharmaceuticals, Inc. (-0.87), greater than Dermata Therapeutics, Inc. (-0.16), greater than Unicycive Therapeutics, Inc. (-1.63), less than Revelation Biosciences, Inc. (-0.13), greater than Affimed N.V. (-0.54), greater than Leap Therapeutics, Inc. (-1.63), greater than Adaptimmune Therapeutics plc (-3.77), greater than Corvus Pharmaceuticals, Inc. (-10.50), greater than Akari Therapeutics, Plc (-0.81), greater than Salarius Pharmaceuticals, Inc. (-0.35), greater than Axcella Health Inc. (-3.07), greater than Magenta Therapeutics, Inc. (-0.15), less than Histogen Inc. (-0.01),

Build a custom stock screener for Mustang Bio, Inc. (MBIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mustang Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mustang Bio, Inc. (MBIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mustang Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.